The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Zoster Vaccine Market Research Report 2025
Synopsis
Highlights
The global Recombinant Zoster Vaccine market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Recombinant Zoster Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Recombinant Zoster Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Recombinant Zoster Vaccine include GSK, Merck and Changchun Bcht Biotechnology, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Recombinant Zoster Vaccine in Above 50 Years Old is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Monovalent Vaccine, which accounted for % of the global market of Recombinant Zoster Vaccine in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Zoster Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Zoster Vaccine.
The Recombinant Zoster Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Recombinant Zoster Vaccine market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Zoster Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
GSK
Merck
Changchun Bcht Biotechnology
Product Type Insights
Global markets are presented by Recombinant Zoster Vaccine type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Recombinant Zoster Vaccine are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Recombinant Zoster Vaccine segment by Type
Monovalent Vaccine
Combination Vaccine
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Recombinant Zoster Vaccine market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Recombinant Zoster Vaccine market.
Recombinant Zoster Vaccine segment by Application
Above 50 Years Old
Below 50 Years Old
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant Zoster Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Zoster Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Recombinant Zoster Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Recombinant Zoster Vaccine industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Zoster Vaccine.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Zoster Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Zoster Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Highlights
The global Recombinant Zoster Vaccine market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Recombinant Zoster Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Recombinant Zoster Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Recombinant Zoster Vaccine include GSK, Merck and Changchun Bcht Biotechnology, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Recombinant Zoster Vaccine in Above 50 Years Old is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Monovalent Vaccine, which accounted for % of the global market of Recombinant Zoster Vaccine in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Zoster Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Zoster Vaccine.
The Recombinant Zoster Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Recombinant Zoster Vaccine market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Zoster Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
GSK
Merck
Changchun Bcht Biotechnology
Product Type Insights
Global markets are presented by Recombinant Zoster Vaccine type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Recombinant Zoster Vaccine are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Recombinant Zoster Vaccine segment by Type
Monovalent Vaccine
Combination Vaccine
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Recombinant Zoster Vaccine market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Recombinant Zoster Vaccine market.
Recombinant Zoster Vaccine segment by Application
Above 50 Years Old
Below 50 Years Old
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant Zoster Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Zoster Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Recombinant Zoster Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Recombinant Zoster Vaccine industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Zoster Vaccine.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Zoster Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Zoster Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Index1 Recombinant Zoster Vaccine Market Overview
1.1 Product Overview and Scope of Recombinant Zoster Vaccine
1.2 Recombinant Zoster Vaccine Segment by Type
1.2.1 Global Recombinant Zoster Vaccine Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Recombinant Zoster Vaccine Segment by Application
1.3.1 Global Recombinant Zoster Vaccine Sales Comparison by Application: (2022-2028)
1.3.2 Above 50 Years Old
1.3.3 Below 50 Years Old
1.4 Global Recombinant Zoster Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant Zoster Vaccine Revenue 2017-2028
1.4.2 Global Recombinant Zoster Vaccine Sales 2017-2028
1.4.3 Recombinant Zoster Vaccine Market Size by Region: 2017 Versus 2021 Versus 2028
2 Recombinant Zoster Vaccine Market Competition by Manufacturers
2.1 Global Recombinant Zoster Vaccine Sales Market Share by Manufacturers (2017-2022)
2.2 Global Recombinant Zoster Vaccine Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Recombinant Zoster Vaccine Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Recombinant Zoster Vaccine Manufacturing Sites, Area Served, Product Type
2.5 Recombinant Zoster Vaccine Market Competitive Situation and Trends
2.5.1 Recombinant Zoster Vaccine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Recombinant Zoster Vaccine Players Market Share by Revenue
2.5.3 Global Recombinant Zoster Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Zoster Vaccine Retrospective Market Scenario by Region
3.1 Global Recombinant Zoster Vaccine Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Recombinant Zoster Vaccine Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Recombinant Zoster Vaccine Market Facts & Figures by Country
3.3.1 North America Recombinant Zoster Vaccine Sales by Country
3.3.2 North America Recombinant Zoster Vaccine Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Recombinant Zoster Vaccine Market Facts & Figures by Country
3.4.1 Europe Recombinant Zoster Vaccine Sales by Country
3.4.2 Europe Recombinant Zoster Vaccine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Recombinant Zoster Vaccine Market Facts & Figures by Region
3.5.1 Asia Pacific Recombinant Zoster Vaccine Sales by Region
3.5.2 Asia Pacific Recombinant Zoster Vaccine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Recombinant Zoster Vaccine Market Facts & Figures by Country
3.6.1 Latin America Recombinant Zoster Vaccine Sales by Country
3.6.2 Latin America Recombinant Zoster Vaccine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Recombinant Zoster Vaccine Market Facts & Figures by Country
3.7.1 Middle East and Africa Recombinant Zoster Vaccine Sales by Country
3.7.2 Middle East and Africa Recombinant Zoster Vaccine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Recombinant Zoster Vaccine Historic Market Analysis by Type
4.1 Global Recombinant Zoster Vaccine Sales Market Share by Type (2017-2022)
4.2 Global Recombinant Zoster Vaccine Revenue Market Share by Type (2017-2022)
4.3 Global Recombinant Zoster Vaccine Price by Type (2017-2022)
5 Global Recombinant Zoster Vaccine Historic Market Analysis by Application
5.1 Global Recombinant Zoster Vaccine Sales Market Share by Application (2017-2022)
5.2 Global Recombinant Zoster Vaccine Revenue Market Share by Application (2017-2022)
5.3 Global Recombinant Zoster Vaccine Price by Application (2017-2022)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Recombinant Zoster Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.1.4 GSK Recombinant Zoster Vaccine Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Recombinant Zoster Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Merck Recombinant Zoster Vaccine Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Changchun Bcht Biotechnology
6.3.1 Changchun Bcht Biotechnology Corporation Information
6.3.2 Changchun Bcht Biotechnology Description and Business Overview
6.3.3 Changchun Bcht Biotechnology Recombinant Zoster Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Changchun Bcht Biotechnology Recombinant Zoster Vaccine Product Portfolio
6.3.5 Changchun Bcht Biotechnology Recent Developments/Updates
7 Recombinant Zoster Vaccine Manufacturing Cost Analysis
7.1 Recombinant Zoster Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Recombinant Zoster Vaccine
7.4 Recombinant Zoster Vaccine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Recombinant Zoster Vaccine Distributors List
8.3 Recombinant Zoster Vaccine Customers
9 Recombinant Zoster Vaccine Market Dynamics
9.1 Recombinant Zoster Vaccine Industry Trends
9.2 Recombinant Zoster Vaccine Market Drivers
9.3 Recombinant Zoster Vaccine Market Challenges
9.4 Recombinant Zoster Vaccine Market Restraints
10 Global Market Forecast
10.1 Recombinant Zoster Vaccine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Recombinant Zoster Vaccine by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Recombinant Zoster Vaccine by Type (2023-2028)
10.2 Recombinant Zoster Vaccine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Recombinant Zoster Vaccine by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Recombinant Zoster Vaccine by Application (2023-2028)
10.3 Recombinant Zoster Vaccine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Recombinant Zoster Vaccine by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Recombinant Zoster Vaccine by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Recombinant Zoster Vaccine Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Recombinant Zoster Vaccine Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Recombinant Zoster Vaccine Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Recombinant Zoster Vaccine Market Competitive Situation by Manufacturers in 2021
Table 5. Global Recombinant Zoster Vaccine Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Recombinant Zoster Vaccine Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Recombinant Zoster Vaccine Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Recombinant Zoster Vaccine Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Recombinant Zoster Vaccine Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Recombinant Zoster Vaccine Manufacturing Sites and Area Served
Table 11. Manufacturers Recombinant Zoster Vaccine Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Recombinant Zoster Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Zoster Vaccine as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Recombinant Zoster Vaccine Sales by Region (2017-2022) & (K Units)
Table 16. Global Recombinant Zoster Vaccine Sales Market Share by Region (2017-2022)
Table 17. Global Recombinant Zoster Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Recombinant Zoster Vaccine Revenue Market Share by Region (2017-2022)
Table 19. North America Recombinant Zoster Vaccine Sales by Country (2017-2022) & (K Units)
Table 20. North America Recombinant Zoster Vaccine Sales Market Share by Country (2017-2022)
Table 21. North America Recombinant Zoster Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Recombinant Zoster Vaccine Revenue Market Share by Country (2017-2022)
Table 23. Europe Recombinant Zoster Vaccine Sales by Country (2017-2022) & (K Units)
Table 24. Europe Recombinant Zoster Vaccine Sales Market Share by Country (2017-2022)
Table 25. Europe Recombinant Zoster Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Recombinant Zoster Vaccine Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Recombinant Zoster Vaccine Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Recombinant Zoster Vaccine Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Recombinant Zoster Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Recombinant Zoster Vaccine Revenue Market Share by Region (2017-2022)
Table 31. Latin America Recombinant Zoster Vaccine Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Recombinant Zoster Vaccine Sales Market Share by Country (2017-2022)
Table 33. Latin America Recombinant Zoster Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Recombinant Zoster Vaccine Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Recombinant Zoster Vaccine Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Recombinant Zoster Vaccine Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Recombinant Zoster Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Recombinant Zoster Vaccine Revenue Market Share by Country (2017-2022)
Table 39. Global Recombinant Zoster Vaccine Sales by Type (2017-2022) & (K Units)
Table 40. Global Recombinant Zoster Vaccine Sales Market Share by Type (2017-2022)
Table 41. Global Recombinant Zoster Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Recombinant Zoster Vaccine Revenue Share by Type (2017-2022)
Table 43. Global Recombinant Zoster Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Recombinant Zoster Vaccine Sales (K Units) by Application (2017-2022)
Table 45. Global Recombinant Zoster Vaccine Sales Market Share by Application (2017-2022)
Table 46. Global Recombinant Zoster Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Recombinant Zoster Vaccine Revenue Share by Application (2017-2022)
Table 48. Global Recombinant Zoster Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 49. GSK Corporation Information
Table 50. GSK Description and Business Overview
Table 51. GSK Recombinant Zoster Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. GSK Recombinant Zoster Vaccine Product
Table 53. GSK Recent Developments/Updates
Table 54. Merck Corporation Information
Table 55. Merck Description and Business Overview
Table 56. Merck Recombinant Zoster Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Merck Recombinant Zoster Vaccine Product
Table 58. Merck Recent Developments/Updates
Table 59. Changchun Bcht Biotechnology Corporation Information
Table 60. Changchun Bcht Biotechnology Description and Business Overview
Table 61. Changchun Bcht Biotechnology Recombinant Zoster Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Changchun Bcht Biotechnology Recombinant Zoster Vaccine Product
Table 63. Changchun Bcht Biotechnology Recent Developments/Updates
Table 64. Production Base and Market Concentration Rate of Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Recombinant Zoster Vaccine Distributors List
Table 67. Recombinant Zoster Vaccine Customers List
Table 68. Recombinant Zoster Vaccine Market Trends
Table 69. Recombinant Zoster Vaccine Market Drivers
Table 70. Recombinant Zoster Vaccine Market Challenges
Table 71. Recombinant Zoster Vaccine Market Restraints
Table 72. Global Recombinant Zoster Vaccine Sales Forecast by Type (2023-2028) & (K Units)
Table 73. Global Recombinant Zoster Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 74. Global Recombinant Zoster Vaccine Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 75. Global Recombinant Zoster Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 76. Global Recombinant Zoster Vaccine Sales Forecast by Application (2023-2028) & (K Units)
Table 77. Global Recombinant Zoster Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 78. Global Recombinant Zoster Vaccine Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 79. Global Recombinant Zoster Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 80. Global Recombinant Zoster Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 81. Global Recombinant Zoster Vaccine Sales Market Share Forecast by Region (2023-2028)
Table 82. Global Recombinant Zoster Vaccine Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 83. Global Recombinant Zoster Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 84. Research Programs/Design for This Report
Table 85. Key Data Information from Secondary Sources
Table 86. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Zoster Vaccine
Figure 2. Global Recombinant Zoster Vaccine Market Share by Type in 2021 & 2028
Figure 3. Monovalent Vaccine Product Picture
Figure 4. Combination Vaccine Product Picture
Figure 5. Global Recombinant Zoster Vaccine Market Share by Application in 2021 & 2028
Figure 6. Above 50 Years Old
Figure 7. Below 50 Years Old
Figure 8. Global Recombinant Zoster Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Recombinant Zoster Vaccine Market Size (2017-2028) & (US$ Million)
Figure 10. Global Recombinant Zoster Vaccine Sales (2017-2028) & (K Units)
Figure 11. Recombinant Zoster Vaccine Sales Share by Manufacturers in 2021
Figure 12. Global Recombinant Zoster Vaccine Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Recombinant Zoster Vaccine Players: Market Share by Revenue in 2021
Figure 14. Recombinant Zoster Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Recombinant Zoster Vaccine Sales Market Share by Region (2017-2022)
Figure 16. Global Recombinant Zoster Vaccine Sales Market Share by Region in 2021
Figure 17. Global Recombinant Zoster Vaccine Revenue Market Share by Region (2017-2022)
Figure 18. Global Recombinant Zoster Vaccine Revenue Market Share by Region in 2021
Figure 19. United States Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Taiwan Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Mexico Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Brazil Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Argentina Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Turkey Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Saudi Arabia Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. UAE Recombinant Zoster Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Sales Market Share of Recombinant Zoster Vaccine by Type (2017-2022)
Figure 42. Manufacturing Cost Structure of Recombinant Zoster Vaccine
Figure 43. Manufacturing Process Analysis of Recombinant Zoster Vaccine
Figure 44. Recombinant Zoster Vaccine Industrial Chain Analysis
Figure 45. Channels of Distribution
Figure 46. Distributors Profiles
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
